Insmed Inc (INSM)
69.29
+1.14
(+1.67%)
USD |
NASDAQ |
Nov 05, 16:00
70.35
+1.06
(+1.53%)
After-Hours: 19:06
Insmed Cash from Financing (Quarterly): 397.20M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 397.20M |
| June 30, 2024 | 781.49M |
| March 31, 2024 | 3.022M |
| December 31, 2023 | 123.26M |
| September 30, 2023 | 1.249M |
| June 30, 2023 | 44.33M |
| March 31, 2023 | -0.399M |
| December 31, 2022 | 743.39M |
| September 30, 2022 | 37.12M |
| June 30, 2022 | 6.311M |
| March 31, 2022 | 6.459M |
| December 31, 2021 | 5.71M |
| September 30, 2021 | 2.536M |
| June 30, 2021 | 597.60M |
| March 31, 2021 | 6.703M |
| December 31, 2020 | 12.01M |
| September 30, 2020 | 6.102M |
| June 30, 2020 | 250.76M |
| March 31, 2020 | 2.134M |
| December 31, 2019 | 9.238M |
| September 30, 2019 | 1.358M |
| June 30, 2019 | 271.63M |
| March 31, 2019 | 3.049M |
| December 31, 2018 | 2.423M |
| September 30, 2018 | 0.605M |
| Date | Value |
|---|---|
| June 30, 2018 | 5.549M |
| March 31, 2018 | 378.17M |
| December 31, 2017 | 0.433M |
| September 30, 2017 | 378.22M |
| June 30, 2017 | 1.869M |
| March 31, 2017 | 0.565M |
| December 31, 2016 | 20.85M |
| September 30, 2016 | 9.692M |
| June 30, 2016 | 0.047M |
| March 31, 2016 | 0.081M |
| December 31, 2015 | -0.139M |
| September 30, 2015 | 0.825M |
| June 30, 2015 | 225.64M |
| March 31, 2015 | 1.475M |
| December 31, 2014 | 6.374M |
| September 30, 2014 | 108.44M |
| June 30, 2014 | -0.06M |
| March 31, 2014 | 0.337M |
| December 31, 2013 | 0.039M |
| September 30, 2013 | 67.79M |
| June 30, 2013 | 0.596M |
| March 31, 2013 | 0.022M |
| December 31, 2012 | 10.13M |
| September 30, 2012 | 25.63M |
| June 30, 2012 | 9.698M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.399M
Minimum
Mar 2023
781.49M
Maximum
Jun 2024
151.81M
Average
7.970M
Median
Cash from Financing (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 0.377M |
| Alnylam Pharmaceuticals Inc | 102.76M |
| Eli Lilly and Co | 211.30M |
| Bioventus Inc | -7.845M |
| Entrada Therapeutics Inc | 101.37M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -180.92M |
| Cash from Investing (Quarterly) | -1.003B |
| Free Cash Flow | -636.03M |
| Free Cash Flow Per Share (Quarterly) | -1.063 |
| Free Cash Flow to Equity (Quarterly) | 31.84M |
| Free Cash Flow to Firm (Quarterly) | -163.45M |
| Free Cash Flow Yield | -5.91% |